Heng Sheng Sow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9165305/publications.pdf

Version: 2024-02-01

1163117 1474206 9 177 8 9 citations g-index h-index papers 9 9 9 368 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. MAbs, 2020, 12, 1685349.	5. 2	11
2	IgE Antibodies against Cancer: Efficacy and Safety. Antibodies, 2020, 9, 55.	2.5	17
3	Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment. Scientific Reports, 2020, 10, 3933.	3.3	6
4	Combined Inhibition of TGF- \hat{l}^2 Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells, 2019, 8, 320.	4.1	82
5	AllergoOncology: Expression platform development and functional profiling of an antiâ€HER2 IgE antibody. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1985-1989.	5.7	14
6	FcγR interaction is not required for effective antiâ€PD‣1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354.	5.1	12
7	A Restricted Role for $Fc\hat{l}^3R$ in the Regulation of Adaptive Immunity. Journal of Immunology, 2018, 200, 2615-2626.	0.8	14
8	High Fc \hat{l}^3R Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy. Journal of Immunology, 2018, 201, 3741-3749.	0.8	11
9	Fc \hat{l}^3 Rl expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. Oncotarget, 2018, 9, 29392-29402.	1.8	10